hypogonadism; testosterone; fda; health

Hitting the nail on the head here! * More than 30 years later, he argues that the regulatory framework no longer reflects current clinical evidence and may be doing more harm than good. In this episode, Arundhati Parmar interviews Shalin Shah, CEO of Marius Pharmaceuticals, about...